Jean Hayes has managed the Vanguard Health Care Fund (Trades, Portfolio) since 2008. The following are stocks that the fund has purchased for the past two quarters.Â
Agios Pharmaceuticals Inc. (AGIO)
During Q4 2015, the fund increased its stake by 2.04% and again by 32.75% in the first quarter 2016. The fund currently holds 8.85% of outstanding shares of the company that is engaged in the development of medicines to treat the cancer metabolism and inborn errors of metabolism, which are a subset of orphan genetic metabolic diseases.
The largest shareholder among the gurus is Columbia Wanger (Trades, Portfolio) with 1.15% of outstanding shares.
Envision Healthcare Holdings Inc. (EVHC)
During Q4 2015, the fund increased its stake by 53.53% and in Q1 2016, again bought shares in the company with another increase of 21.76%. The fund currently holds 5.88% of outstanding shares of the company that is engaged in providing physician-led, outsourced medical services in the U.S. Fourth quarter results demonstrated continued growth and the progress the company is making as it executes on focused initiatives to further strengthen operating performance, particularly at EmCare in which net revenue increased by 28%.
Andreas Halvorsen (Trades, Portfolio) is the largest shareholder of the company among the gurus with 4.17% of outstanding shares, followed by Columbia Wanger (Trades, Portfolio) with 0.8%, Steven Cohen (Trades, Portfolio) with 0.31%, and Jim Simons (Trades, Portfolio) with 0.23%.
Baxter International Inc. (BAX)
During Q4 2015, the fund increased its stake by 32.84% and again by 2.04% in the first quarter of 2016. The fund currently holds 2.04% of outstanding shares of the company that is engaged in the development, manufacture and sale of products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. During the fourth quarter, worldwide sales totaled $2.6 billion, an increase of 2% on a constant currency basis as compared to the prior year period, and also exceeded the company’s previously issued guidance.
The largest shareholder among the gurus is Daniel Loeb (Trades, Portfolio) with 9.83% of outstanding shares, followed by Jana Partners (Trades, Portfolio) with 1.04%, Richard Pzena (Trades, Portfolio) with 0.86%, Tweedy Browne (Trades, Portfolio) with 0.46%, Mairs and Power (Trades, Portfolio) with 0.42%, Tweedy Browne (Trades, Portfolio) Global Value with 0.2%, Steven Cohen (Trades, Portfolio) with 0.16%, First Eagle Investment (Trades, Portfolio) with 0.15% and Louis Moore Bacon (Trades, Portfolio) with 0.11%.
Alnylam Pharmaceuticals Inc. (ALNY)
During Q4 2015, the fund increased its stake by 3.10% and in first quarter of 2016, again bought shares in the company with another increase of 12.25% of its stake. The fund currently holds 10% of outstanding shares of the biopharmaceutical company that develops novel therapeutics based on RNA interference, or RNAi. The company's research and development is focused primarily on use of its proprietary N-acetylgalactosamine, or GalNAc-conjugate for delivery of small interfering RNAs, or "siRNAs" - the molecules that mediate RNAi - toward liver-expressed genes involved in the cause or pathway of human diseases.
John Griffin (Trades, Portfolio) is the largest shareholder of the company among the gurus with 1.26% of outstanding shares, followed by John Paulson (Trades, Portfolio) with 0.01% and George Soros (Trades, Portfolio) with 0.01%.
Walgreens Boots Alliance Inc. (WBA)
During Q4 2015, the fund increased its stake by 8.75% and again by 9.43% in the first quarter 2016. The fund currently holds 0.75% of outstanding shares of the company that operates drugstores in the U.S. The company provides consumer goods and services, pharmacy, and health and wellness services in communities across the U.S. Adjusted second quarter net earnings attributable to Walgreens Boots Alliance per diluted share increased 11% and net earnings increased 14.4%.
The largest shareholder among the gurus is Andreas Halvorsen (Trades, Portfolio) with 1.18% of outstanding shares, followed by Jana Partners (Trades, Portfolio) with 1.14%, Steve Mandel (Trades, Portfolio) with 0.63% and Bill Gates (Trades, Portfolio) with 0.23%.
Cerner Corp. (CERN)
During Q4 2015, the fund increased its stake by 3.63% and in Q1, again bought shares in the company with another increase of 3.20% of its stake. The fund currently holds 4.98% of outstanding shares of the company that is a supplier of health care information technology and offers solutions and services that support the clinical, financial and operational needs of organizations. Bookings in the fourth quarter of 2015 were $1.35 billion, an increase of 16% and revenue was $1.175 billion, an increase of 27%.
Frank Sands (Trades, Portfolio) is the largest shareholder of the company among the gurus with 3.97% of outstanding shares, followed by Manning & Napier Advisors with 2.04%, Meridian Funds (Trades, Portfolio) with 0.29%, Ron Baron (Trades, Portfolio) with 0.07%, Louis Moore Bacon (Trades, Portfolio) with 0.05%, Jim Simons (Trades, Portfolio) with 0.02% and PRIMECAP Management (Trades, Portfolio) with 0.01%.
Vertex Pharmaceuticals Inc. (VRTX)
During Q4 2015, the fund increased its stake by 4.34% and in Q1, again bought shares in the company with another increase of 28.91% of its stake. The fund currently holds 5.12% of outstanding shares of the company that is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets.
The largest shareholder among the gurus is Andreas Halvorsen (Trades, Portfolio) with 0.57% of outstanding shares, followed by Spiros Segalas (Trades, Portfolio) with 0.45%, Pioneer Investments (Trades, Portfolio) with 0.31%, Samuel Isaly (Trades, Portfolio) with 0.07% and John Paulson (Trades, Portfolio) with 0.02%.
McKesson Corp. (MCK)
During Q4 2015, the fund increased its stake by 2.30% and again by 8.24% in the first quarter 2016. The fund currently holds 3.13% of outstanding shares of the company that delivers pharmaceuticals, medical supplies and health care information technology that make health care safer while reducing costs.
Andreas Halvorsen (Trades, Portfolio) is the largest shareholder of the company among the gurus with 1.21% of outstanding shares, followed by Larry Robbins (Trades, Portfolio) with 0.96%, Pioneer Investments (Trades, Portfolio) with 0.1%, Arnold Van Den Berg (Trades, Portfolio) with 0.03%, Jerome Dodson (Trades, Portfolio) with 0.03%, Manning & Napier Advisors with 0.02%, Ray Dalio (Trades, Portfolio) with 0.02% and First Pacific Advisors (Trades, Portfolio) with 0.02%.
Incyte Corp. (INCY)
During Q4 2015, the fund increased its stake by 4.15% and in Q1, again bought shares in the company with another increase of 68.76%. The fund currently holds 8.67% of outstanding shares of the biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology.
The largest shareholder among the gurus is Frank Sands (Trades, Portfolio) with 2.36% of outstanding shares, followed by Samuel Isaly (Trades, Portfolio) with 0.23% and Ken Fisher (Trades, Portfolio) with 0.01%.
